There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (UHS – Research Report), Ultragenyx Pharmaceutical (RARE – Research Report) and Opthea Limited Sponsored ADR (OPT – Research Report) with bullish sentiments.
Universal Health (UHS)
Leerink Partners analyst Whit Mayo reiterated a Buy rating on Universal Health on April 3 and set a price target of $192.00. The company’s shares closed last Friday at $173.43, close to its 52-week high of $183.61.
According to TipRanks.com, Mayo is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Universal Health with a $187.29 average price target, an 8.4% upside from current levels. In a report issued on March 28, Wells Fargo also maintained a Buy rating on the stock with a $200.00 price target.
See today’s best-performing stocks on TipRanks >>
Ultragenyx Pharmaceutical (RARE)
Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Ultragenyx Pharmaceutical on April 3 and set a price target of $98.00. The company’s shares closed last Friday at $50.24.
According to TipRanks.com, Schwartz is a 2-star analyst with an average return of
Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $87.29, representing an 87.4% upside. In a report issued on March 19, Stifel Nicolaus also maintained a Buy rating on the stock with a $124.00 price target.
Opthea Limited Sponsored ADR (OPT)
Leerink Partners analyst Marc Goodman maintained a Buy rating on Opthea Limited Sponsored ADR on April 3. The company’s shares closed last Friday at $4.00, close to its 52-week high of $4.42.
According to TipRanks.com, Goodman is a 4-star analyst with an average return of
Currently, the analyst consensus on Opthea Limited Sponsored ADR is a Moderate Buy with an average price target of $14.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on UHS:
- Universal Health falls after subsidiary hit with $535M jury verdict
- Universal Health price target raised to $185 from $175 at Stephens
- Universal Health Sets 2024 Executive Incentive Bonuses
- Universal Health price target raised to $183 from $161 at RBC Capital
- Universal Health price target raised to $200 from $175 at Mizuho
